Phase I study of roniciclib (BAY1000394), an oral CDK inhibitor in Japanese patients with advanced solid tumors

被引：0
|
作者：
Seto, Takashi [1 ]
Nosaki, Kaname [1 ]
Shinoda, Gen [2 ]
Hashizume, Kensei [2 ]
Yamaguchi, Iku [2 ]
Tsuburaya, Jun [2 ]
Nogai, Hendrik [3 ]
Shitara, Kohei [4 ]
Yoh, Kiyotaka [4 ]
机构：
[1] Kyushu Natl Canc Ctr, Fukuoka, Japan
[2] Bayer Yakuhin Ltd, Osaka, Japan
[3] Bayer Pharma AG, Berlin, Germany
[4] Natl Canc Ctr Hosp East, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O3-5-3
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I study of oral rigosertib in patients with advanced solid tumors
    Bowles, Daniel W.
    Diamond, Jennifer Robinson
    Lam, Elaine Tat
    Messersmith, Wells A.
    Weekes, Colin D.
    Leong, Stephen
    Gore, Lia
    Lieu, Christopher Hanyoung
    Freas, Elizabeth
    Ren, Chen
    Wilhelm, Francois
    Eckhardt, S. Gail
    Jimeno, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] A phase I study of oral ixabepilone in patients with advanced solid tumors
    John F. Deeken
    John L. Marshall
    Michael J. Pishvaian
    Jimmy Hwang
    Christoph M. Ahlers
    Pamela L. Clemens
    Susan M. Parker
    Lisa Iacono
    Patricia M. LoRusso
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 1071 - 1078
  • [23] A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
    Akira Fukutomi
    Kiyohiko Hatake
    Kaoru Matsui
    Sakura Sakajiri
    Tomonori Hirashima
    Hiromi Tanii
    Ken Kobayashi
    Nobuyuki Yamamoto
    Investigational New Drugs, 2012, 30 : 1096 - 1106
  • [24] A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
    Wagner, Andrew J.
    Messersmith, Wells A.
    Shaik, M. Naveed
    Li, Sherry
    Zheng, Xianxian
    McLachlan, Karen R.
    Cesari, Rossano
    Courtney, Rachel
    Levin, Wendy J.
    El-Khoueiry, Anthony B.
    CLINICAL CANCER RESEARCH, 2015, 21 (05) : 1044 - 1051
  • [25] Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination with gemcitabine in advanced solid tumors
    Bahleda, R.
    Spreafico, A.
    Soria, J.
    Moldovan, C.
    Belli, C.
    Fiorentini, F.
    Scaburri, A.
    Pacciarini, M. A.
    Laffranchi, B.
    Reni, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors
    Aurora Norman
    Mahesh Seetharam
    Jacob Allred
    Jianping Kong
    Mateusz Opyrchal
    Wen Wee Ma
    Yanyan Lou
    Grace K. Dy
    Amit Mahipal
    S. John Weroha
    Andrea E. Wahner Hendrickson
    Joel M. Reid
    Alex A. Adjei
    BJC Reports, 3 (1):
  • [27] Final results of a Phase I study of cediranib, a VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
    Murakami, H.
    Yamamoto, N.
    Boku, N.
    Yamazaki, K.
    Yamamoto, N.
    Yamada, Y.
    Yamada, K.
    Puchalski, T.
    Shin, E.
    Tamura, T.
    EJC SUPPLEMENTS, 2008, 6 (12): : 124 - 124
  • [28] Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Uenaka, Kazunori
    Sekiguchi, Risa
    Makiuchi, Takeshi
    Slapak, Christopher A.
    Benhadji, Karim A.
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1645 - 1655
  • [29] Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors
    Noboru Yamamoto
    Hiroshi Nokihara
    Yasuhide Yamada
    Kazunori Uenaka
    Risa Sekiguchi
    Takeshi Makiuchi
    Christopher A. Slapak
    Karim A. Benhadji
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1645 - 1655
  • [30] Phase I study of CFI-402257, an oral TTK inhibitor, in patients with advanced solid tumors.
    Cescon, David W.
    Hansen, Aaron Richard
    Razak, Albiruni Ryan Abdul
    Stayner, Lee-Anne
    Hilton, John Frederick
    Renouf, Daniel John
    Denny, Trisha
    Fletcher, Graham
    Mak, Tak W.
    Bray, Mark R.
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345